AFP and hepatocellular carcinoma: Currently, AFP is the most widely used biomarker in HCC; however, AFP-negative cases have been observed in many patients with advanced HCC, highlighting the urgent need for new biomarkers that can complement AFP to enable the early diagnosis of HCC and to improve patient survival rates (26).